Restless legs syndrome due to interferon-α
✍ Scribed by Jeffrey S. LaRochelle; Barbara I. Karp
- Publisher
- John Wiley and Sons
- Year
- 2004
- Tongue
- English
- Weight
- 47 KB
- Volume
- 19
- Category
- Article
- ISSN
- 0885-3185
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
A patient developed restless legs symptoms paralleling the course of interferon‐α (IFNα) therapy for chronic hepatitis C. Symptoms began during a course of IFNα, resolved with its suspension, and recurred on rechallenge. Restless legs syndrome may thus be an adverse effect of IFNα treatment. © 2004 Movement Disorder Society
📜 SIMILAR VOLUMES
## Abstract The neuroanatomical substrate for restless legs syndrome (RLS) is unknown. We identified 4 patients with idiopathic RLS who came to post‐mortem examination, where brain and spinal cord tissue were available for neuropathological assessment. Lewy bodies were not identified and α‐synuclei
## Abstract α‐Melanocyte stimulating hormone (α‐MSH) and adrenocorticotropic hormone (ACTH) possess properties suggesting that they may be involved in the pathogenesis of restless legs syndrome (RLS). We sought to determine if α‐MSH and ACTH when administered centrally in rat recapitulate features
## Abstract Although restless legs syndrome (RLS) commonly accompanies Parkinson disease (PD), the mechanism of RLS development in PD is still unclear. We investigated the prevalence of RLS in Korean patients with PD, and the possible contributing factors to the development of RLS in those patients